Innovative Research Award
Mohamed Husseiny Elsayed
Beckman Research Institute of City of Hope
The Innovative Research Award recognizes distinguished scientific achievements that contribute to the advancement of biomedical and pharmaceutical sciences. Mohamed Husseiny Elsayed has developed a research profile characterized by sustained contributions to immunotherapy, translational oncology, and therapeutic innovation. His scholarly output has supported the understanding of immune-mediated mechanisms and their application in clinical research environments.[1]
Abstract
This article presents an academic overview of Mohamed Husseiny Elsayed and his suitability for recognition through the Innovative Research Award. The assessment is based on publication activity, citation performance, research visibility, and contributions to immunotherapy-related investigations. Available scholarly indicators demonstrate consistent engagement with impactful biomedical research and collaborative scientific advancement.[2]
Keywords
Immunotherapy, translational medicine, oncology research, biomedical innovation, pharmaceutical sciences, clinical investigation, scientific impact, therapeutic development.
Introduction
Modern biomedical research increasingly depends on interdisciplinary approaches that integrate molecular biology, immunology, and clinical sciences. Researchers working in these domains contribute to the development of therapeutic strategies designed to address complex diseases. Mohamed Husseiny Elsayed has participated in this evolving scientific landscape through research efforts focused on immunotherapeutic applications and translational outcomes.[3]
Research Profile
The researcher is affiliated with the Beckman Research Institute of City of Hope in the United States. Bibliometric indicators report 65 indexed documents, more than 6,300 citations, and an h-index of 28. These metrics suggest sustained scholarly engagement and measurable visibility within the scientific community, particularly in immunotherapy-related disciplines.[1]
Research Contributions
Research contributions attributed to Mohamed Husseiny Elsayed include studies exploring immune responses, cancer therapeutics, and translational research methodologies. His collaborative publications have supported scientific understanding of treatment optimization and biological mechanisms relevant to disease management. Such work aligns with contemporary priorities in precision medicine and advanced therapeutic development.[4]
Publications
The publication record of Mohamed Husseiny Elsayed includes 65 scholarly documents in immunotherapy and translational oncology, reflecting sustained research productivity, scientific collaboration, and contributions to advancing biomedical knowledge and therapeutic innovation.[4]
Research Impact
Citation activity represents one indicator of scientific influence and knowledge dissemination. With thousands of citations recorded across indexed publications, the researcher demonstrates meaningful engagement from the academic community. The observed citation profile suggests that published findings have contributed to ongoing discussions and developments within biomedical research fields.[3]
Award Suitability
Evaluation for the Innovative Research Award considers originality, scholarly productivity, scientific influence, and relevance to advancing healthcare knowledge. Based on available academic indicators, Mohamed Husseiny Elsayed demonstrates characteristics commonly associated with recognized research excellence. His publication record, citation performance, and institutional affiliation collectively support consideration within competitive academic recognition programs.[2]
Conclusion
The academic profile presented in this article highlights measurable research activity and scholarly engagement within the field of immunotherapy. Bibliometric indicators, institutional affiliation, and documented scientific contributions collectively illustrate an established research trajectory. These characteristics provide a foundation for recognition within academic and professional award frameworks dedicated to scientific innovation.[1]
External Links
References
- Elsevier. (n.d.). Scopus author details: Mohamed Husseiny Elsayed, Author ID 8580986700. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=8580986700
- ORCID. (n.d.). Researcher Profile: Mohamed Husseiny Elsayed.
https://orcid.org/0000-0002-3470-2858
- Cobb, J., Rawson, J., Gonzalez, N., Kandeel, F., & Husseiny, M. I. (n.d.). Oral tolerogenic vaccine combined with gastrin restores immune tolerance and beta-cell function in NOD mice with type 1 diabetes.
https://pubmed.ncbi.nlm.nih.gov/41635853/
- Singer, M., Hamdy, R., Ghonaim, J.H., & Husseiny, M.I. Metabolic Imbalance in Immune Cells in Relation to Metabolic Disorders, Cancer, and Infections.
https://link.springer.com/chapter/10.1007/978-981-96-1305-2_9